UCB S.A.
UCB
Xếp hạng trong cổ phiếu
#523
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Giá cổ phiếu
$242.33
Vốn hóa thị trường
$46.20B
Thay đổi (1 ngày)
-0.15%
Thay đổi (1 năm)
-16.40%
Quốc gia
BE
Giao dịch UCB S.A. (UCB)
Danh mục
Healthcare
Lịch sử cổ tức của UCB S.A. (UCB)
UCB S.A. (mã cổ phiếu: UCB) đã thực hiện tổng cộng 29 lần chi trả cổ tức.
Tổng tất cả cổ tức (đã điều chỉnh theo chia tách cổ phiếu): $27.69
Tỷ suất cổ tức (TTM): 0.0072
Tổng tất cả cổ tức (đã điều chỉnh theo chia tách cổ phiếu): $27.69
Tỷ suất cổ tức (TTM): 0.0072
Các khoản chi trả cổ tức của UCB S.A. (UCB) từ 2000 đến 2026
Các khoản chi trả cổ tức hàng năm
| Năm | Cổ tức (đã điều chỉnh chia tách cổ phiếu) | Thay đổi |
|---|---|---|
| 2026 (TTM) | $1.20 | 0.00% |
| 2025 | $1.20 | -11.98% |
| 2024 | $1.36 | 2.26% |
| 2023 | $1.33 | 2.31% |
| 2022 | $1.30 | 2.36% |
| 2021 | $1.27 | 2.42% |
| 2020 | $1.24 | 2.48% |
| 2019 | $1.21 | 2.54% |
| 2018 | $1.18 | 2.61% |
| 2017 | $1.15 | 4.55% |
| 2016 | $1.10 | 3.77% |
| 2015 | $1.06 | 1.92% |
| 2014 | $1.04 | 1.96% |
| 2013 | $1.02 | 2.00% |
| 2012 | $1.00 | 2.04% |
| 2011 | $0.98 | 2.08% |
| 2010 | $0.96 | 4.35% |
| 2009 | $0.92 | 0.00% |
| 2008 | $0.92 | 2.22% |
| 2007 | $0.9 | 2.27% |
| 2006 | $0.88 | 2.33% |
| 2005 | $0.86 | -34.85% |
| 2004 | $1.32 | 9.09% |
| 2003 | $1.21 | 6.14% |
| 2002 | $1.14 | 78.13% |
| 2001 | $0.64 | 28.00% |
| 2000 | $0.5 | 0.00% |
Danh sách tất cả các khoản chi trả cổ tức
| Năm | Cổ tức | Thay đổi |
|---|---|---|
| 2026 (TTM) | $1.20 | 0.00% |
| 2025 | $1.20 | -11.98% |
| 2024 | $1.36 | 2.26% |
| 2023 | $1.33 | 2.31% |
| 2022 | $1.30 | 2.36% |
| 2021 | $1.27 | 2.42% |
| 2020 | $1.24 | 2.48% |
| 2019 | $1.21 | 2.54% |
| 2018 | $1.18 | 2.61% |
| 2017 | $1.15 | 4.55% |
| 2016 | $1.10 | 3.77% |
| 2015 | $1.06 | 1.92% |
| 2014 | $1.04 | 1.96% |
| 2013 | $1.02 | 2.00% |
| 2012 | $1.00 | 2.04% |
| 2011 | $0.98 | 2.08% |
| 2010 | $0.96 | 4.35% |
| 2009 | $0.92 | 0.00% |
| 2008 | $0.92 | 2.22% |
| 2007 | $0.9 | 2.27% |
| 2006 | $0.88 | 2.33% |
| 2005 | $0.86 | -34.85% |
| 2004 | $1.32 | 9.09% |
| 2003 | $1.21 | 6.14% |
| 2002 | $1.14 | 78.13% |
| 2001 | $0.64 | 28.00% |
| 2000 | $0.5 | 0.00% |
Cổ tức của các công ty tương tự hoặc đối thủ
| Công ty | Số lần chi trả cổ tức | Quốc gia |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
